Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon
Cancers – April 27, 2024
Source: OpenAlex
Summary
Psilocybin shows promise in psychiatry for cancer-related depression, but its path to becoming accessible medicine faces hurdles. Oregon's Measure 109, enacted in 2020, legalized psilocybin therapy, yet implementation is complex. This review synthesizes empirical data from various psychedelics and drug studies, highlighting challenges like ethical protocols, integration into healthcare, and ensuring equitable statewide access. Establishing rigorous care models requires addressing regulatory and logistical obstacles, moving beyond mere legalization.
Abstract
Despite the legalization of psilocybin therapy for depression in terminal illnesses such as advanced cancer through Oregon’s Measure 109 in 2020, significant challenges have impeded its implementation. This review synthesizes the empirical data supporting the utilization of psilocybin therapy for addressing cancer-related depression, including an evaluation of its purported benefits and potential adverse effects. It provides a comprehensive examination of therapeutic strategies, dosing regimens, and barriers to ensuring responsible and equitable access. Salient issues explored include the development of ethical protocols, integration within healthcare systems, ensuring statewide availability, resolving legal ambiguities, and defining clinical standards. Oregon’s pioneering role serves as a case study, highlighting the necessity of addressing regulatory, logistical, and ethical obstacles to ensure the establishment of rigorous and equitable psilocybin care models.